Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT327 + Chemotherapy in Triple-negative Breast Cancer
NCT06449222Phase 2Active, not recruiting
- Sponsor
- BioNTech SE
- Start
- Aug 2024
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of pumitamig in triple-negative breast cancer (TNBC), sponsored by BioNTech SE. Started Aug 2024; status: active, not recruiting.
02
Drugs
pumitamig
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06449222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449222.